At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVAX Novavax
Not Yet Opened 05-02 16:00:00 EDT
4.71
+0.04
+0.86%
盘后4.65
-0.06-1.27%
19:59 EDT
High4.78
Low4.60
Vol3.69M
Open4.69
D1 Closing4.67
Amplitude3.85%
Mkt Cap656.58M
Tradable Cap580.34M
Total Shares139.40M
T/O17.32M
T/O Rate2.99%
Tradable Shares123.21M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Recent uptick might appease Novavax, Inc. (NASDAQ:NVAX) institutional owners after losing 35% over the past year
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.